1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow Recurrent Vulvar Carcinoma: new trials by email Literature Review of Recurrent Vulvar Carcinoma trials Research Report on Recurrent Vulvar Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab - Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive | Phase 2 | Terminated | M.D. Anderson Cancer Center | 41 | 2018-11-14 | 2024-07-09 |
Anal Canal Carcinoma (1) · Anus Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Penile Neoplasms (1) · Recurrence (1) · Uterine Cervical Neoplasms (1) · Vaginal Neoplasms (1) · Vulvar Neoplasms (1)
Anus Diseases (1) · Colorectal Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Diseases, Male (1) · Genital Neoplasms, Female (1) · Genital Neoplasms, Male (1) · Intestinal Diseases (1)
Disulfides (1) · Immunoglobulin G (1) · MEDI0457 (1) · VGX-3100 (1) · durvalumab (1) · rocakinogene sifuplasmid (1)
M.D. Anderson Cancer Center (1)
United States (1)